Is Increasing the Dose of Entecavir Effective in Partial Virological Responders?

Overview

Journal Drug Des Devel Ther

Specialty Pharmacology

Date 2014 Jun 18

PMID 24936126

Citations 1

Authors

Ayse Erturk

Remzi Adnan Akdogan

Emine Parlak

Erkan Cure

Medine Cumhur Cure

Cinar Ozturk

Affiliations

Soon will be listed here.

Abstract

Objective: To analyze the effect of increasing Entecavir (ETV) dosage in patients with chronic hepatitis B (CHB) who partially responded to ETV after 1 year.

Methods: Twenty-three hepatitis B e antigen (HBeAg)-positive and 36 HBeAg-negative patients with CHB were treated with ETV 0.5 mg daily. After 1 year of the treatment, those with detectable hepatitis B virus (HBV-DNA) were randomized to either ETV 0.5 mg or 1 mg daily. The resistance to ETV was excluded. Both groups received ETV for 3 years. The groups were compared in aspects of undetectable DNA.

Results: Group 1 was given 0.5 mg ETV and included 32 patients (20 HBeAg-negative and 12 HBeAg-positive). Group 2 was given 1 mg ETV and consisted of 27 patients (16 HBeAg-negative and eleven HBeAg-positive). Group 2 had more effective suppression of HBV-DNA while both groups had comparable rates of HBeAg loss (58% and 63% for group 1 and group 2, respectively) and alanine transaminase (ALT) normalization at the end of 4 years.

Conclusion: Increasing ETV dose from 0.5 mg to 1 mg after 1 year of ETV treatment may provide an effective suppression of viral replication.

Citing Articles

Severe de novo Hepatitis B Recovered from Late-Onset Liver Insufficiency with Prolonged Ascites and Hypoalbuminemia due to Hepatitis B Virus Genotype Bj with Precore Mutation.

Sato A, Ishii T, Sano F, Yamada T, Takahashi H, Matsumoto N Case Rep Gastroenterol. 2016; 10(3):553-559.

PMID: 27920641 PMC: 5121562. DOI: 10.1159/000450543.

References

Zoutendijk R, Reijnders J, Brown A, Zoulim F, Mutimer D, Deterding K . Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naïve patients with a partial virological response. Hepatology. 2011; 54(2):443-51. DOI: 10.1002/hep.24406. View

Yuen M, Lai C . Treatment of chronic hepatitis B: Evolution over two decades. J Gastroenterol Hepatol. 2011; 26 Suppl 1:138-43. DOI: 10.1111/j.1440-1746.2010.06545.x. View

Ha N, Ha N, Chaung K, Trinh H, Nguyen H, Nguyen K . Similar response to entecavir 0.5 and 1.0 mg in treatment-naïve chronic hepatitis B patients: a case-control study. Dig Dis Sci. 2013; 59(1):168-73. DOI: 10.1007/s10620-013-2940-2. View

Marcellin P, Heathcote E, Buti M, Gane E, de Man R, Krastev Z . Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med. 2008; 359(23):2442-55. DOI: 10.1056/NEJMoa0802878. View

Keating G . Entecavir: a review of its use in the treatment of chronic hepatitis B in patients with decompensated liver disease. Drugs. 2011; 71(18):2511-29. DOI: 10.2165/11208510-000000000-00000. View

Hadziyannis S, Tassopoulos N, Heathcote E, Chang T, Kitis G, Rizzetto M . Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med. 2005; 352(26):2673-81. DOI: 10.1056/NEJMoa042957. View

Santantonio T, Mazzola M, Iacovazzi T, Miglietta A, Guastadisegni A, Pastore G . Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine. J Hepatol. 2000; 32(2):300-6. DOI: 10.1016/s0168-8278(00)80076-8. View

Pol S, Lampertico P . First-line treatment of chronic hepatitis B with entecavir or tenofovir in 'real-life' settings: from clinical trials to clinical practice. J Viral Hepat. 2012; 19(6):377-86. PMC: 3489060. DOI: 10.1111/j.1365-2893.2012.01602.x. View

Baldick C, Eggers B, Fang J, Levine S, Pokornowski K, Rose R . Hepatitis B virus quasispecies susceptibility to entecavir confirms the relationship between genotypic resistance and patient virologic response. J Hepatol. 2008; 48(6):895-902. DOI: 10.1016/j.jhep.2007.12.024. View

10.

Heathcote E, Marcellin P, Buti M, Gane E, de Man R, Krastev Z . Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology. 2010; 140(1):132-43. DOI: 10.1053/j.gastro.2010.10.011. View

11.

Chang T, Gish R, Hadziyannis S, Cianciara J, Rizzetto M, Schiff E . A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients. Gastroenterology. 2005; 129(4):1198-209. DOI: 10.1053/j.gastro.2005.06.055. View

12.

Shouval D, Lai C, Chang T, Cheinquer H, Martin P, Carosi G . Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: the case for continuous antiviral therapy. J Hepatol. 2008; 50(2):289-95. DOI: 10.1016/j.jhep.2008.10.017. View

13.

Chang T, Lai C, Yoon S, Lee S, Coelho H, Carrilho F . Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology. 2010; 51(2):422-30. DOI: 10.1002/hep.23327. View

14.

Yuen M, Seto W, Fung J, Wong D, Yuen J, Lai C . Three years of continuous entecavir therapy in treatment-naïve chronic hepatitis B patients: VIRAL suppression, viral resistance, and clinical safety. Am J Gastroenterol. 2011; 106(7):1264-71. DOI: 10.1038/ajg.2011.45. View

15.

Tenney D, Rose R, Baldick C, Pokornowski K, Eggers B, Fang J . Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy. Hepatology. 2009; 49(5):1503-14. DOI: 10.1002/hep.22841. View

16.

Yurdaydin C . Entecavir: a step forward in combating hepatitis B disease. Expert Opin Pharmacother. 2008; 9(17):3095-109. DOI: 10.1517/14656560802515546. View

17.

Gish R, Chang T, Lai C, De Man R, Gadano A, Poordad F . Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B. J Viral Hepat. 2009; 17(1):16-22. DOI: 10.1111/j.1365-2893.2009.01146.x. View

18.

Zoutendijk R, Reijnders J, Zoulim F, Brown A, Mutimer D, Deterding K . Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis. Gut. 2012; 62(5):760-5. DOI: 10.1136/gutjnl-2012-302024. View

19.

Khungar V, Han S . A Systematic Review of Side Effects of Nucleoside and Nucleotide Drugs Used for Treatment of Chronic Hepatitis B. Curr Hepat Rep. 2010; 9(2):75-90. PMC: 2861763. DOI: 10.1007/s11901-010-0039-1. View

20.

. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol. 2012; 57(1):167-85. DOI: 10.1016/j.jhep.2012.02.010. View